Vestal Point Capital LP Grows Stake in Establishment Labs Holdings Inc. $ESTA

Key Points

• Vestal Point Capital LP increased its holdings in Establishment Labs by **44.4%**, now owning **433,193 shares**, making it the firm's 28th largest position.
• Establishment Labs recently reported a revenue of **$51.30 million**, up **16.1%** year-over-year, while posting an earnings loss of **($0.57) per share**, below the consensus estimate.
• Several analysts have upgraded their ratings for Establishment Labs, with price targets ranging from **$47.00 to $70.00**, reflecting a mixed outlook on the stock's potential.

Vestal Point Capital LP boosted its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 44.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 433,193 shares of the company's stock after purchasing an additional 133,193 shares during the period. Establishment Labs comprises approximately 1.3% of Vestal Point Capital LP's investment portfolio, making the stock its 28th biggest position. Vestal Point Capital LP owned 1.50% of Establishment Labs worth $17,676,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC bought a new stake in Establishment Labs during the first quarter worth $207,000. New York State Common Retirement Fund bought a new position in shares of Establishment Labs in the 1st quarter valued at $894,000. Northern Trust Corp lifted its stake in shares of Establishment Labs by 53.9% in the 4th quarter. Northern Trust Corp now owns 28,165 shares of the company's stock valued at $1,298,000 after acquiring an additional 9,865 shares during the last quarter. Swiss National Bank lifted its stake in shares of Establishment Labs by 1.3% in the 1st quarter. Swiss National Bank now owns 39,000 shares of the company's stock valued at $1,591,000 after acquiring an additional 500 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Establishment Labs by 15.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock valued at $2,196,000 after acquiring an additional 6,307 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Mizuho increased their price target on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. BTIG Research assumed coverage on Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 price objective for the company. Canaccord Genuity Group assumed coverage on Establishment Labs in a report on Wednesday, August 20th. They issued a "buy" rating and a $60.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and issued a $48.00 price objective on shares of Establishment Labs in a research report on Friday, June 13th. Finally, Wall Street Zen lowered Establishment Labs from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $56.50.

Establishment Labs Stock Up 0.9%

Shares of ESTA traded up $0.36 during trading hours on Friday, hitting $39.03. The stock had a trading volume of 173,812 shares, compared to its average volume of 392,709. The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67. The firm has a 50 day simple moving average of $41.41 and a 200-day simple moving average of $37.90. The firm has a market capitalization of $1.13 billion, a P/E ratio of -12.80 and a beta of 0.85. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $50.85.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The business had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.80 million. During the same period in the previous year, the business posted ($0.62) EPS. Establishment Labs's revenue was up 16.1% compared to the same quarter last year. Establishment Labs has set its FY 2025 guidance at EPS. Sell-side analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.